-
Information-Publications
-
Additional mutations based on Omicron BA. 2.75 mediate its further evasion from broadly neutralizing antibodiesDetails -
Circ_0087199 depletion attenuates lipopolysaccharides‐induced human periodontal ligament cell injury through the miR‐527/TLR4 axisDetails -
D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunityDetails -
Salvianolate ameliorates renal tubular injury through the Keap1/Nrf2/ARE pathway in mouse kidney ischemia-reperfusion injuryDetails -
NSUN2 stimulates tumor progression via enhancing TIAM2 mRNA stability in pancreatic cancerDetails -
CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cellsDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
